Targeted treatment of non-small cell lung cancer

被引:0
|
作者
Scheffler, Matthias [1 ]
Michels, Sebastian [1 ]
Nogova, Lucia [1 ]
机构
[1] Univ Klinikum Koln AoR, Klin Innere Med 1, Ctr Integrierte Onkol CIO Aachen Bonn Koln Dussel, Lung Canc Grp Cologne, Kerpener Str 62, D-50937 Cologne, Germany
来源
INNERE MEDIZIN | 2022年 / 63卷 / 07期
关键词
Mutation; KRAS; EGFR; BRAF; Molecular genetic analysis; Drug resistance; neoplasm; OPEN-LABEL; ACQUIRED-RESISTANCE; INTEGRATED ANALYSIS; 1ST-LINE TREATMENT; EGFR MUTATIONS; CHEMOTHERAPY; MULTICENTER; CRIZOTINIB; PHASE-3; EFFICACY;
D O I
10.1007/s00108-022-01372-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Non-small cell lung cancer (NSCLC) has made a remarkable development in recent decades with respect to its perception. In the late 1990s it was the "problem child" as the main cause of cancer with increasing tendencies, especially in women and with a pronounced stigmatization. It is now the role model as a biologically rational targeted treatment based on molecular dependencies of the tumor with a vast improvement of the traditionally poor survival times. Molecular tumor boards have long followed the NSCLC example in the assessment of targeted treatment approaches for other tumor entities. This review article gives an overview of the current possibilities for targeted treatment of NSCLC, which nowadays are applicable for nearly one third of all patients with NSCLC.
引用
收藏
页码:700 / 708
页数:9
相关论文
共 50 条
  • [1] Advances in the targeted treatment of non-small cell lung cancer
    Ruge, Lea
    John, Felix
    Scharpenseel, Heather
    Wolf, Juergen
    INNERE MEDIZIN, 2024, 65 (03): : 211 - 219
  • [2] Non-Small Cell Lung Cancer Targeted Therapy: Drugs and Mechanisms of Drug Resistance
    Wu, Jiajia
    Lin, Zhenghong
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (23)
  • [3] Current Targeted Therapies for the Fight against Non-Small Cell Lung Cancer
    Mustachio, Lisa Maria
    Roszik, Jason
    PHARMACEUTICALS, 2020, 13 (11) : 1 - 14
  • [4] Treatment of KRAS-Mutant Non-Small Cell Lung Cancer The End of the Beginning for Targeted Therapies
    Kaufman, Jacob
    Stinchcombe, Thomas E.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 317 (18): : 1835 - 1837
  • [5] A pharmacological exploration of targeted drug therapy in non-small cell lung cancer
    Jayan, Ajay P.
    Anandu, K. R.
    Madhu, Krishnadas
    Saiprabha, V. N.
    MEDICAL ONCOLOGY, 2022, 39 (10)
  • [6] Molecular targeted therapy of patients with non-small-cell lung cancer
    Stencel, Katarzyna
    Swiniuch, Daria
    Ramlau, Rodryg
    ONCOLOGY IN CLINICAL PRACTICE, 2019, 15 (06): : 289 - 296
  • [7] Targeted Therapy for Non-Small Cell Lung Cancer
    Jett, James R.
    Carr, Laurie L.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 188 (08) : 907 - 912
  • [8] Targeted Therapy for Non-Small Cell Lung Cancer
    Noor, Zorawar S.
    Cummings, Amy L.
    Johnson, McKenna M.
    Spiegel, Marshall L.
    Goldman, Jonathan W.
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 41 (03) : 409 - 434
  • [9] Therapeutic impact of molecular diagnosis in metastatic non-small cell lung cancer: Targeted therapies in 2013
    Pecuchet, N.
    Bigot, F.
    Henni, M.
    Fabre, E.
    REVUE DE PNEUMOLOGIE CLINIQUE, 2014, 70 (1-2) : 38 - 46
  • [10] Treatment of oncogene-driven non-small cell lung cancer
    Kastelijn, Elisabeth A.
    de Langen, Adrianus J.
    Peters, Bas J. M.
    CURRENT OPINION IN PULMONARY MEDICINE, 2019, 25 (03) : 300 - 307